



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/521,455	01/14/2005	Helmut Goldmann	26569U	8794

20529 7590 10/31/2007
NATH & ASSOCIATES
112 South West Street
Alexandria, VA 22314

EXAMINER

SCHILLINGER, ANN M

ART UNIT	PAPER NUMBER
----------	--------------

3774

MAIL DATE	DELIVERY MODE
-----------	---------------

10/31/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/521,455

Applicant(s)

GOLDMANN, HELMUT

Examiner

Ann Schillinger

Art Unit

3774

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 10 August 2007.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 18,25,27,28,30 and 32-34 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 18,25,27,28,30 and 32-34 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 18, 25, 27, and 32-34 are rejected under 35 U.S.C. 103(a) as being anticipated by Trogolo et al. (U.S. Pat. No. 6,296,863) in view of Pourrezai et al. (U. S. Pat. No. 5,685,961). Trogolo et al. discloses the following of claim 18: a vascular prosthesis (col. 1, lines 28-37) for replacement of hollow organs with antibiotic long-term action with a basic structure which defines the form of the prosthesis and which is made of substantially non-absorbable or only slowly absorbable polymer material (10, 18; col. 3, lines 2-4, 15-21) and of a coating of an absorbable material (col. 8, lines 31-40), with a layer of metallic silver (20; col. 3, lines 66 through col. 4, lines 30) situated on the polymer material and underneath the coating (col. 8, lines 9-22, 31-40 indicates that the collagen coating disclosed above is added last over the base and the silver layer). Also Trogolo et al. discloses the prosthesis' porosity in col. 2, lines 56 through col. 3, lines 2 and col. 8, lines 18-33.

However, Trogolo et al. does not disclose choosing the thickness of the silver layer coating so that it will be break down in the body over a desired period of time. In the medical device field, Pourrezai et al. teaches in col. 7, lines 33-39 that the relative decomposition rate of silver is known, therefore the thickness of the silver layer may be calculated according to how long a particular patient will need the medical device to be implanted. Therefore, it would have

Art Unit: 3774

been obvious to one of ordinary skill in the art at the time the invention was made to make the silver layer thick enough to last for the necessary period of time with the decomposition rate of the silver coatings being known. In addition, it would have been obvious to one having ordinary skill in the art at the time the invention was made to create a silver layer that breaks down 5 to 10% of the layer per annum, since it has been held that where the general conditions of a claim are disclosed in the prior art, discovering the optimum or workable ranges involves only routine skill in the art. *In re Aller*, 105 USPQ 233.

Regarding the use of vapor-deposition to distribute the silver atoms, it has been held that a comparison of the recited process with the prior art processes does NOT serve to resolve the issue concerning patentability of the product. *In re Fessman*, 489 F2d 742, 180 U.S.P.Q. 324 (CCPA 1974). Whether a product is patentable depends on whether it is known in the art or it is obvious, and is not governed by whether the process by which it is made is patentable. *In re Klug*, 333 F2d 905, 142 U.S.P.Q. 161 (CCPA 1964). In an ex parte case, product-by-process claims are not construed as being limited to the product formed by the specific process recited. *In re Hirao et al.*, 353 F2d 67, 190 U.S.P.Q. 15, see footnote 3 (CCPA 1976).

Trogolo et al. discloses the following of claim 25: the prosthesis as claimed in claim 18, wherein the silver layer is composed exclusively of elemental silver (col. 6, lines 1-7).

Trogolo et al. discloses the following of claim 27: the prosthesis as claimed in claim 18, wherein the absorbable coating is formed from optionally crosslinked biological material (col. 8, lines 31-33).

Trogolo et al. discloses the following of claim 32: the prosthesis as claimed in claim 31, wherein the fibers of the textile basic structure are coated with silver at least at the locations which point toward at least one surface of the prosthesis (see Figure 4).

Trogolo et al. discloses the following of claim 33: the prosthesis as claimed in claim 32, wherein substantially the entire surface of the fibers being coated with silver (see Figure 4).

Trogolo et al. discloses the following of claim 34: the prosthesis as claimed in claim 18, wherein the basic structure is made from a sintered material (col. 3, lines 2-4).

Claims 28 and 30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Trogolo et al. in view of Pourrezai et al. in further view of Shikani et al. (U. S. Pat. No. 5,762,638).

Regarding claim 28, Trogolo et al. and Pourrezai et al. do not disclose using a synthetic polymers as the absorbable coating on the outside of the prosthesis. In the field of medical devices, Shikani et al. teaches in col. 14, lines 8-25, 37-47 that synthetic polymers and co-polymers make excellent coating materials on prosthetic devices because they are not prone to swelling and are non bioerodible. Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to potentially replace Trogolo et al.'s collagen coating with a synthetic polymer as both are known in the art to have properties that are necessary for coatings on prosthetics.

Regarding claim 30, Trogolo et al. and Pourrezai et al. do not disclose using active substances in the absorbable coating. Shikani et al. teaches in col. 5, lines 47-62 that it is known in the art to place drugs in the outer coating of a device such that it can be programmed to be released after a certain period of time based on the choice of the outer coating. This will help

Art Unit: 3774

prevent inflammation and granulation tissue at the sites where these prosthetics are implanted. Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to use such an outer coating on Trogolo et al.'s prosthesis to prevent inflammation and granulation tissue at the site of implantation. In addition, it would have been obvious to one having ordinary skill in the art at the time the invention was made to chose a coating that is absorbed after four months at the latest, since it has been held that discovering an optimum value of a result effective variable involves only routine skill in the art. *In re Boesch*, 617 F.2d 272, 205 USPQ 215 (CCPA 1980).

Response to Arguments

Applicant's arguments filed 8/10//2007 have been fully considered but they are not persuasive. The rejections with Trogolo et al. in view of Burrell et al. or Lawson et al. have been withdrawn for the rejections and case law cited above, as they have been amended to the independent claim. Regarding Trogolo et al., element 20 is shown as a layer in Figure 4 and has the claimed silver as described in col. 3, lines 66 through col. 4, lines 30. This layer is located underneath the collagen coating as described in col. 8, lines 9-22, 31-40. Regarding Pourrezai et al. the absorbable material was not taught by this reference, but by the Trogolo et al. reference. Also, the Applicant contends that Pourrezai et al. cannot be combined with Trogolo et al. because they are different devices. It has been held that the determination that a reference is from a nonanalogous art is twofold. First, we decide if the reference is within the field of the inventor's endeavor. IF it is not, we proceed to determine whether the reference is reasonably pertinent to the particular problem with which the inventor was involved. *In re Wood*, 202

Art Unit: 3774

UPSPQ 171, 174. In this case, both prior art inventions are directed towards medical devices, so they are not considered nonanalogous art.

Regarding Shikani et al., this reference was only used to address the limitations of the anti-infective agents, as the other limitations had already been addressed by the previous references.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ann Schillinger whose telephone number is (571) 272-6652. The examiner can normally be reached on Mon. thru Fri. 9 a.m. to 4 p.m..

Art Unit: 3774

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Corrine McDermott can be reached on (571) 272-4754. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Ann Schillinger
October 28, 2007



CORRINE McDERMOTT
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 3700